Articles scientifiques

Imbalance between supply and need of medical oncologists in Belgium

Auteurs : Dhondt V, Benahmed A, De Wever L, Dirix L, de Valeriola D
Année : 2013
Journal : Belgian J Medical Oncology
Volume : 7(2)
Pages : 38-45

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer.

Auteurs : Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S
Année : 2013
Journal : Clin Cancer Res
Volume : 19(1)
Pages : 28-33

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Auteurs : Criscitiello C, Azim HA, Agbor-Tarh D, de Azambuja E, Piccart-Gebhart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT
Année : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1980-5

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. (published online 11/2012)

Auteurs : Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart-Gebhart M, Pierga JY
Année : 2013
Journal : Cancer Metastasis Rev
Volume : 32(1-2
Pages : 179-88

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Auteurs : Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M
Année : 2013
Journal : Breast Cancer Res. Treat.
Volume : 139(1)
Pages : 13-22

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Auteurs : Peccatori FA, Azim HA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G
Année : 2013
Journal : Ann Oncol
Volume : 24 Suppl 6
Pages : vi160-70

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.(epub nov 2013)

Auteurs : Awada A, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart-Gebhart M, Schöffski P
Année : 2013
Journal : Invest New Drugs
Volume : 31(3)
Pages : 734-41

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Auteurs : Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart M
Année : 2013
Journal : Cancer Treat Rev
Volume : 39(8)
Pages : 935-46

Breast cancer arising at a young age: Do we need to define a cut-off?

Auteurs : Azim HA, Azim H
Année : 2013
Journal : Breast
Volume : 22(6)
Pages : 1007-8

Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.

Auteurs : Maisonobe JA, Garcia C, Necib H, Vanderlinden B, Hendlisz A, Flamen P, Buvat I
Année : 2013
Journal : Eur J Nucl Med Mol Imaging
Volume : 40(2)
Pages : 166-74

Supportive care in cancer patients: a unifying concept.

Auteurs : Klastersky J
Année : 2013
Journal : Curr Opin Oncol
Volume : 25(4)
Pages : 341

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial.

Auteurs : Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber Rd, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(16)
Pages : 1954-60

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Auteurs : Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F
Année : 2012
Journal : Ann Oncol
Volume : 23 Suppl 7
Pages : vii155-66

Dissecting the heterogeneity of triple-negative breast cancer.

Auteurs : Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M
Année : 2012
Journal : J. Clin. Oncol.
Volume : 30(15)
Pages : 1879-87

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Auteurs : Criscitiello C, Metzger-Filho O, Saini KS, de Castro G, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart M
Année : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : 209

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Auteurs : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Année : 2012
Journal : Oncogene
Volume : 31(31)
Pages : 3569-83

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Auteurs : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Année : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 612-22

Technological innovation and healthcare professionals' workloads: an ambiguous relationship.

Auteurs : de Pires DE, Bertoncini JH, Trindade Lde L, Matos E, de Azambuja E, Borges AM
Année : 2012
Journal : Rev Gaucha Enferm
Volume : 33(1)
Pages : 157-68

Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?

Auteurs : Gombos A, Metzger-Filho O, Dal Lago L, Awada A
Année : 2012
Journal : Invest New Drugs
Volume : 30(6)
Pages : 2433-42